Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398879 · ClinicalTrials.gov registry record · Phase 2
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Phase 2 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 2
- Development phase
- 381
- Enrollment target
NCT00398879: Completed Phase 2 study, sponsored by AEterna Zentaris.
NCT00398879 is a Phase 2 study that has completed, run by AEterna Zentaris. The registered enrollment target is 381 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (186% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398879, a Phase 2 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 381 participants
- Enrollment target
Study Summary
This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal cancer which would be randomized to either capecitabine plus perifosine or capecitabine alone. The effects of perifosine may be manifested by increased time to progression, tumor regression reflected in partial or complete responses, or a combination of these outcomes. The primary goal of this trial is to obtain a preliminary and objective assessment of the effects of perifosine on time to progression.
Primary Outcome
Time to progression will be measured from the first day of study drug until progression.
Interventions
- DRUG Capecitabine
- DRUG Perifosine
- OTHER Perifosine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00398879 record still lists
NCT00398879 is an interventional study that assigns participants to a tested intervention. The registered 381 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (186% higher).
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00398879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00398879 about?
NCT00398879 is a clinical study titled "Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients". This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal cancer which would be randomized to either capecitabine plus perifosine or ...
What is the current status of trial NCT00398879?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 381 participants. The study started on 2005-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00398879?
The interventions under investigation include: Capecitabine (DRUG), Perifosine (DRUG), Perifosine Placebo (OTHER).
Who is sponsoring clinical trial NCT00398879?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00398879's enrollment target sits among peer trials
381 111th of 2000 higher than 1,890 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05677490 · 382 participants · Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- NCT06196008 · 382 participants · NA
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
- NCT07100990 · 382 participants · Phase 3
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia